On January 23, 2026, Tigress Financial initiated coverage of Walmart with a price target of $135, implying upside of 14.59% from recent levels. Over the past month, Walmart’s share price has climbed 6.94%, outpacing the Retail-Wholesale sector’s 4.28% gain and the S&P 500’s 0.71% advance. Despite a modest 1.25% pullback in the latest session, the stock has demonstrated resilience, trading in a narrow intraday range of $117.14 to $118.61 and closing at $117.78. Investors view this relative strength as a signal of confidence in Walmart’s ability to navigate a competitive retail landscape against peers such as Amazon and Target.

Analysts forecast Walmart will report earnings per share of $0.73 for the quarter ending January, representing a year-over-year increase of 10.61%. Revenue is projected at $190.04 billion, up 5.25% from the same period in fiscal 2025, driven by continued expansion of e-commerce sales and margin improvements in its core U.S. operations. With a market capitalization near $939 billion and a one-year trading range between $79.81 and $121.62, Walmart’s fundamentals suggest it is well positioned to deliver on both top-line growth and cost-efficiency targets when it reports results on February 19, 2026.

This spring, Walmart plans to launch clinical research sites in a limited number of its retail locations and former outpatient health clinic facilities. The initiative aims to leverage the company’s existing real-estate footprint to support pharmaceutical trials and consumer health studies, broadening Walmart’s healthcare services beyond its established pharmacy and vision centers. While details on the number of sites and trial partners have yet to be disclosed, the move underscores management’s strategy to diversify revenue streams and enhance customer engagement through value-added health offerings.